Literature DB >> 26327491

Competing risk bias in Kaplan-Meier risk estimates can be corrected.

Carl van Walraven1, Steven Hawken2.   

Abstract

BACKGROUND: Kaplan-Meier (KM) analyses are frequently used to measure outcome risk over time. These analyses overestimate risk whenever competing events are present. Many published KM analyses are susceptible to such competing risk bias. This study derived and validated a model that predicted true outcome risk based on the biased KM risk.
METHODS: We simulated survival data sets having a broad range of 1-year true outcome and competing event risk. Unbiased true outcome risk estimates were calculated using the cumulative incidence function (CIF). Multiple linear regression was used to determine the independent association of CIF-based true outcome risk with the biased KM risk and the proportion of all outcomes that were competing events.
RESULTS: The final model found that both the biased KM-based risk and the proportion of all outcomes that were competing events were strongly associated with CIF-based risk. In validation populations that used a variety of distinct survival hazard functions, the model accurately predicted the CIF (R(2) = 1).
CONCLUSIONS: True outcome risk can be accurately predicted from KM estimates susceptible to competing risk bias.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bias; Competing risks; Cumulative incidence function; Kaplan-Meier estimates; Product-limit; Survival analysis

Mesh:

Year:  2015        PMID: 26327491     DOI: 10.1016/j.jclinepi.2015.08.010

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

1.  [Development and validation of a prognostic model based on SEER data for patients with esophageal carcinoma after esophagectomy].

Authors:  C Luo; G Wang; L Hu; Y Qiang; C Zheng; Y Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

2.  Risk Factors of Relapse After Smoking Cessation: Results in China Family Panel Studies From 2010 to 2018.

Authors:  Naifan Hu; Zhenfan Yu; Yurun Du; Jiangping Li
Journal:  Front Public Health       Date:  2022-07-01

3.  Pretreatment Aspartate Aminotransferase-to-Alanine Aminotransferase (De Ritis) Ratio Predicts the Prognosis of Nonmetastatic Nasopharyngeal Carcinoma.

Authors:  Jiayuan Wu; Shasha Li; Yufeng Wang; Liren Hu
Journal:  Onco Targets Ther       Date:  2019-11-22       Impact factor: 4.147

4.  Trends in conditional overall survival of esophageal cancer: a population-based study.

Authors:  Wei Deng; Rong Yu; Zhao Yang; Xin Dong; Weihu Wang
Journal:  Ann Transl Med       Date:  2021-01

5.  Development and validation of an online prognostic nomogram for osteosarcoma after surgery: a retrospective study based on the SEER database and external validation with single-center data.

Authors:  Liwen Feng; Yuting Chen; Ting Ye; Zengwu Shao; Chengzhi Ye; Jing Chen
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

6.  In-utero cigarette smoke exposure and the risk of earlier menopause.

Authors:  Talita C Honorato; Maaike L Haadsma; Jolande A Land; Marike H Boezen; Annemieke Hoek; Henk Groen
Journal:  Menopause       Date:  2018-01       Impact factor: 2.953

7.  Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma.

Authors:  Anfeng Si; Jun Li; Hongjun Xiang; Shichao Zhang; Shilei Bai; Pinghua Yang; Xiaofeng Zhang; Yong Xia; Kui Wang; Zhenlin Yan; Wan Yee Lau; Lehua Shi; Feng Shen
Journal:  Oncotarget       Date:  2017-07-04

8.  Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database.

Authors:  Peng Fu; Yu Shi; Gang Chen; Yaohua Fan; Yanhong Gu; Zhenzhen Gao
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Prevalence and incidence of cognitive impairment in an elder Portuguese population (65-85 years old).

Authors:  Ricardo Pais; Luís Ruano; Carla Moreira; Ofélia P Carvalho; Henrique Barros
Journal:  BMC Geriatr       Date:  2020-11-16       Impact factor: 3.921

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.